{"log_id": 6823023826990081025, "direction": 0, "words_result_num": 25, "words_result": [{"probability": {"variance": 8e-06, "average": 0.998479, "min": 0.985932}, "location": {"width": 801, "top": 228, "height": 45, "left": 222}, "words": "有发生此类事件风险或此类事件病史的患者应慎用阿昔替尼。目前尚未在之前12"}, {"probability": {"variance": 1.4e-05, "average": 0.997406, "min": 0.983529}, "location": {"width": 518, "top": 290, "height": 40, "left": 179}, "words": "个月内发生动脉血栓栓塞事件的患者中研究阿昔替尼"}, {"probability": {"variance": 4.3e-05, "average": 0.996055, "min": 0.978932}, "location": {"width": 184, "top": 353, "height": 32, "left": 178}, "words": "静脉血栓栓塞事件"}, {"probability": {"variance": 0.000113, "average": 0.996208, "min": 0.951256}, "location": {"width": 802, "top": 394, "height": 44, "left": 223}, "words": "临床试验已报告包括死亡在内的静脉血栓栓塞事件。在接受阿昔替尼治疗RCC的"}, {"probability": {"variance": 3.5e-05, "average": 0.997594, "min": 0.966064}, "location": {"width": 846, "top": 448, "height": 46, "left": 179}, "words": "患者对照临床试验中,接受阿昔替尼治疗的11359例患者(3%)和接受索拉非尼治疗"}, {"probability": {"variance": 0.011829, "average": 0.968977, "min": 0.398908}, "location": {"width": 846, "top": 503, "height": 46, "left": 180}, "words": "的2/355例患者(1%)报告静脉血栓栓塞事件。接受阿昔替尼治疗的9359例患者(3%)"}, {"probability": {"variance": 1e-05, "average": 0.998192, "min": 0.98557}, "location": {"width": 836, "top": 558, "height": 45, "left": 189}, "words": "(包括肺栓塞、深静脉血栓、视网膜静脉闭塞、视网膜静脉血栓)和接受索拉非尼治疗"}, {"probability": {"variance": 0.013294, "average": 0.953363, "min": 0.462485}, "location": {"width": 825, "top": 612, "height": 45, "left": 181}, "words": "的2/355例患者(1%)报告3/4级静脉血栓栓塞事件。致死性肺栓塞见于1/359例(<1%"}, {"probability": {"variance": 1.8e-05, "average": 0.998323, "min": 0.977915}, "location": {"width": 833, "top": 666, "height": 44, "left": 181}, "words": "接受阿昔替尼治疗的患者,接受索拉非尼治疗的患者无报告。在阿昔替尼临床试验中"}, {"probability": {"variance": 0.003039, "average": 0.980803, "min": 0.692789}, "location": {"width": 758, "top": 721, "height": 45, "left": 183}, "words": "有22/715例患者(3%)报告静脉血栓栓塞事件,其中2例死亡继发于肺栓塞"}, {"probability": {"variance": 0.001037, "average": 0.993163, "min": 0.803482}, "location": {"width": 804, "top": 775, "height": 44, "left": 228}, "words": "存在这些事件风险或曾有这些事件病史的患者应慎用阿昔替尼。目前尚未在之前6"}, {"probability": {"variance": 0.004272, "average": 0.66933, "min": 0.603966}, "location": {"width": 51, "top": 740, "height": 121, "left": 1026}, "words": "油图"}, {"probability": {"variance": 1.4e-05, "average": 0.997789, "min": 0.982971}, "location": {"width": 518, "top": 835, "height": 41, "left": 185}, "words": "个月内发生静脉血栓栓塞事件的患者中研究阿昔替尼"}, {"probability": {"variance": 0.001967, "average": 0.982882, "min": 0.836711}, "location": {"width": 278, "top": 895, "height": 34, "left": 183}, "words": "血红蛋白成血细胞比容升高"}, {"probability": {"variance": 6.8e-05, "average": 0.997134, "min": 0.953079}, "location": {"width": 808, "top": 939, "height": 43, "left": 224}, "words": "阿昔替尼治疗过程中可能发生血红蛋白或血细胞比容升高,反映红细胞总量增加"}, {"probability": {"variance": 1.5e-05, "average": 0.997104, "min": 0.984498}, "location": {"width": 646, "top": 996, "height": 43, "left": 194}, "words": "(见【不良反应】)。红细胞总量增加可能增加血栓栓塞事件的风险"}, {"probability": {"variance": 1.9e-05, "average": 0.998258, "min": 0.977677}, "location": {"width": 802, "top": 1048, "height": 45, "left": 230}, "words": "应在开始阿昔替尼治疗前并在治疗过程中定期监测血红蛋白或血细胞比容。如果血"}, {"probability": {"variance": 0.000107, "average": 0.995824, "min": 0.953888}, "location": {"width": 847, "top": 1101, "height": 47, "left": 186}, "words": "红蛋白或血细胞比容升高至高于正常水平,应根据常规对患者进行治疗,将血红蛋白或"}, {"probability": {"variance": 8e-06, "average": 0.997407, "min": 0.991844}, "location": {"width": 320, "top": 1166, "height": 37, "left": 187}, "words": "血细胞比容降低至可接受的水平"}, {"probability": {"variance": 0, "average": 0.999476, "min": 0.999284}, "location": {"width": 48, "top": 1229, "height": 26, "left": 188}, "words": "出血"}, {"probability": {"variance": 0.000178, "average": 0.994488, "min": 0.926103}, "location": {"width": 804, "top": 1266, "height": 46, "left": 232}, "words": "在接受阿昔替尼治疗的RCC患者对照临床研究中,接受阿昔替尼治疗的58/359例"}, {"probability": {"variance": 0.00069, "average": 0.990811, "min": 0.835605}, "location": {"width": 845, "top": 1321, "height": 48, "left": 190}, "words": "患者(16%)和接受索拉非尼治疗的64/355例患者(18%)报告出血事件。接受阿昔替"}, {"probability": {"variance": 0.005632, "average": 0.975677, "min": 0.579721}, "location": {"width": 846, "top": 1377, "height": 49, "left": 190}, "words": "尼治疗的5359(1%)例患者和接受索拉非尼治疗的11/355(3%)例患者报告314级出"}, {"probability": {"variance": 0.002218, "average": 0.978864, "min": 0.85525}, "location": {"width": 131, "top": 1585, "height": 25, "left": 553}, "words": "第9页,共27页"}, {"probability": {"variance": 0.007032, "average": 0.962823, "min": 0.74128}, "location": {"width": 69, "top": 1617, "height": 21, "left": 280}, "words": "20150429"}], "language": 3}